Neural Stem Cell (NSC) Therapy for Neurological Repair — Regenerative Therapies
CNS-derived progenitor cells for neurological conditions including spinal cord injury, ALS, stroke, and neurodegenerative diseases.
Overview
Neural Stem Cells (NSCs) are self-renewing multipotent cells that give rise to neurons, astrocytes, and oligodendrocytes. NSCs reside in specific brain regions (subventricular zone, hippocampal dentate gyrus) throughout life but have limited endogenous regenerative capacity after injury. Exogenous NSC transplantation aims to replace lost neurons, provide trophic support, remyelinate axons, and modulate neuroinflammation. Clinical trials have investigated NSC transplantation for spinal cord injury, ALS (Neuralstem NSI-566), chronic ischemic stroke (CTX0E03 - ReNeuron), and Pelizaeus-Merzbacher disease. Challenges include limited cell survival post-transplant, difficulty achieving functional neural circuit integration, immune rejection requiring immunosuppression, and the blood-brain barrier limiting systemic delivery approaches.
Indications
- Spinal cord injury (chronic and subacute)
- Amyotrophic lateral sclerosis (ALS)
- Chronic ischemic stroke
- Pelizaeus-Merzbacher disease (PMD - leukodystrophy)
- Parkinson's disease
- Traumatic brain injury
- Multiple sclerosis (remyelination)
- Cerebral palsy
Mechanism of Action
NSCs derived from fetal CNS tissue, adult brain biopsy, or iPSC-directed differentiation. Expanded in vitro as neurospheres or adherent cultures with EGF/FGF-2 mitogens
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Human Spinal Cord-Derived NSCs | 6-12 injections of 100,000 cells each | Single surgical session | Intraspinal injection for ALS (Neuralstem NSI-566 trial) |
| CTX0E03 Neural Stem Cells | 20 million cells | Single injection | Intracerebral injection for chronic stroke (ReNeuron CTX0E03) |
| Human CNS Stem Cells | 70 million cells (4 injections) | Single surgical session | Direct brain injection for PMD (HuCNS-SC) |
Evidence Grade
GRADE C
Safety & Contraindications
- Invasive delivery: requires surgical implantation into brain or spinal cord
- Immunosuppression required for allogeneic transplants
- Risk of graft overgrowth or ectopic tissue formation
- Limited cell survival: majority of transplanted NSCs die within days to weeks
- Functional integration into existing neural circuits remains challenging
- Risk of neuropathic pain from aberrant neural connections
- Blood-brain barrier limits non-invasive delivery methods
- Very limited clinical data - small Phase 1/2 trials with 10-20 patients